The article provides an overview of analyst ratings for Editas Medicine (EDIT) in the last 3 months. The average 12-month price target has increased by 33.36% over the past month, which may indicate a positive sentiment among analysts. However, the short-term impact on the stock price is uncertain as the ratings are spread across bullish, somewhat bullish, and indifferent categories.